Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E
Hamamatsu University School of Medicine and Honda Motor Co., Ltd., Japan.
Ann Intern Med. 1998 Dec 15;129(12):1027-30. doi: 10.7326/0003-4819-129-12-199812150-00006.
Omeprazole is metabolized by S-mephenytoin 4'-hydroxylase (CYP2C19) in the liver. In persons with a poor-metabolizer genotype for CYP2C19, the therapeutic efficacy of omeprazole may be increased.
To investigate whether CYP2C19 genotype status is associated with cure rates for Helicobacterpylori infection and peptic ulcer achieved by using dual therapy with omeprazole and amoxicillin.
Prospective cohort study.
University hospital and health service center in Hamamatsu, Japan.
62 patients with peptic ulcer and H. pylori infection.
Omeprazole and amoxicillin.
CYP2C19 genotype status and cure rates for H. pylori infection and peptic ulcer.
Cure rates for H. pylori infection were 28.6% (95% CI, 13.1% to 48.7%), 60% (CI, 38.6% to 83.0%), and 100% (CI, 66.4% to 100%) in the rapid-, intermediate-, and poor-metabolizer groups, respectively. Healing rates for both duodenal and gastric ulcer in the three groups were roughly parallel with cure rates for H. pylori infection.
The results of the genotyping test for CYP2C19 seem to predict cure of H. pylori infection and peptic ulcer in patients who receive dual therapy with omeprazole and amoxicillin.
奥美拉唑在肝脏中由S-美芬妥英4'-羟化酶（CYP2C19）代谢。对于CYP2C19代谢不良基因型的人，奥美拉唑的治疗效果可能会增强。
研究CYP2C19基因型状态与使用奥美拉唑和阿莫西林联合治疗实现的幽门螺杆菌感染治愈率及消化性溃疡治愈率是否相关。
前瞻性队列研究。
日本滨松的大学医院和健康服务中心。
62例患有消化性溃疡和幽门螺杆菌感染的患者。
奥美拉唑和阿莫西林。
CYP2C19基因型状态以及幽门螺杆菌感染和消化性溃疡的治愈率。
快速代谢组、中间代谢组和慢代谢组的幽门螺杆菌感染治愈率分别为28.6%（95%CI，13.1%至48.7%）、60%（CI，38.6%至83.0%）和100%（CI，66.4%至100%）。三组十二指肠溃疡和胃溃疡的愈合率与幽门螺杆菌感染治愈率大致平行。
CYP2C19基因分型检测结果似乎可以预测接受奥美拉唑和阿莫西林联合治疗的患者的幽门螺杆菌感染及消化性溃疡的治愈情况。
